University of Augsburg

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Retrieved on: 
Wednesday, June 28, 2023
Research, Clinical Trials, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Faculty, University of Augsburg, Radiation, Gland, Society, University, Medical school, SNMMI, TI, Molecular imaging, PSMA, Therapeutic index, Society of Nuclear Medicine and Molecular Imaging, Bone marrow, PET, Nuclear medicine, Doctor of Philosophy, Trial of the century, BET, Spleen, Patient, Annual general meeting, Kidney, Liver, Neoplasm, Therapy, Disease, Safety, Prostate cancer, Medical imaging, Medicine, MD

177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical for the treatment of prostate cancer.

Key Points: 
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical for the treatment of prostate cancer.
  • Also being presented are results of Blue Earth Therapeutics’ preclinical studies that examined the therapeutic dose response of 177Lu-rhPSMA-10.1 and the therapeutic efficacy of 177Lu-rhPSMA-10.1 as compared to several other compounds.
  • 177Lu-rhPSMA-10.1 is the first clinical candidate in Blue Earth Therapeutics’ oncology development program of advanced targeted therapeutic radiopharmaceuticals.
  • The preclinical efficacy results in prostate cancer xenografts reported here support a promising therapeutic profile for 177Lu-rhPSMA-10.1.

Paessler acquires qbilon to help customers unlock key insights to improve IT performance

Retrieved on: 
Wednesday, May 3, 2023
OT, JSON, University of Augsburg, University, Marketing, Culture, Internet of things, VMware, Intelligence, Research, History, Gesellschaft mit beschränkter Haftung, Aggregation, Acquisition, CSV, Workload, Architecture, AWS, Retail, Sales, Paessler PRTG, Dynatrace

NUREMBERG, Germany, May 3, 2023 /PRNewswire/ --  Paessler AG, the IT monitoring specialist best known for the monitoring software Paessler PRTG, acquires qbilon GmbH, a company that provides a platform for automatically capturing, analyzing and optimizing hybrid IT landscapes.

Key Points: 
  • qbilon was founded in 2019 by four computer science research fellows at the University of Augsburg and retains its headquarters in Augsburg, Germany.
  • Through the acquisition, Paessler will add IT transparency solutions to its extensive portfolio of service offerings.
  • "As our first ever acquisition, today marks an exciting milestone in our history and future," said Helmut Binder, CEO of Paessler.
  • We are looking forward to providing our joint customers with comprehensive knowledge about their IT landscapes to help drive efficiencies and save resources.

Martin Borutta Recognized for Excellence in Industrial Machinery and Equipment

Retrieved on: 
Tuesday, November 2, 2021
Librarian, Engineering, Research, Religion, University, Ludwig Maximilian University of Munich, Industry, Knowledge, Marquess, Munich University of Applied Sciences, View, Business administration, Medicine, Master of Business Administration, Technology, Joy, Politics, Edition (book), Environment, Multimedia, University of Augsburg, Applied science, Education, Prefabrication, Management

PINEVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Martin Borutta is a distinguished biographee of Marquis Who's Who.

Key Points: 
  • PINEVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Martin Borutta is a distinguished biographee of Marquis Who's Who.
  • Born in Germany, Mr. Borutta began his professional career as the technical director for the U2 Office of Buromobelfabrik GmbH & Co. from 1993 until 1995.
  • Mr. Borutta subsequently advanced to become the technical director for the Trend Office of Buromobelfabrik GmbH & Co., which is a manufacturer of executive office desks, conference room equipment and other office furniture.
  • Thanks to his stellar reputation in the German industrial machinery and equipment space, Mr. Borutta was appointed as the chief executive officer of TTK Technology GmbH from 2003 until 2007.

Satisfai Health acquires global license for AI software to detect early cancer in Barrett's Esophagus

Retrieved on: 
Thursday, September 16, 2021
Institute of technology, Artificial intelligence, Shoulder, Barrett's esophagus, University, Associate, Technology, Teaching hospital, GI, Applied science, Patient, Colon, University of Oxford, European Society of Neurogastroenterology and Motility, Esophageal cancer, Gastrointestinal Endoscopy, University of Augsburg, Endoscopy, Extrapyramidal system, Dysplasia, Technical University of Applied Sciences Wildau, Esophagus, Google Images, Medical image computing, ESGE, OTH, Gastrointestinal disease, Research, John Radcliffe Hospital, Health, Medical device, Medical imaging

VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ -- Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusive global license from the University of Augsburg and the OTH Regensburg, Technical University of Applied Sciences, in Germany. Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable. Barrett's is a gastrointestinal condition affecting around 150 million people globally. Terms of the transaction were not disclosed.

Key Points: 
  • Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable.
  • Satisfai Health's licensing of AI-enhanced software will provide clinicians with faster, more effective diagnostics during endoscopic procedures.
  • Diagnosis entails imaging and biopsies of the esophagus to check for precancerous cells (dysplasia) which can be treated to prevent esophageal cancer.
  • Satisfai Health is a leading medical solutions provider specializing in AI applications for gastroenterology.

Satisfai Health acquires global license for AI software to detect early cancer in Barrett's Esophagus

Retrieved on: 
Thursday, September 16, 2021
Institute of technology, Artificial intelligence, Shoulder, Barrett's esophagus, University, Associate, Technology, Teaching hospital, GI, Applied science, Patient, Colon, University of Oxford, European Society of Neurogastroenterology and Motility, Esophageal cancer, Gastrointestinal Endoscopy, University of Augsburg, Endoscopy, Extrapyramidal system, Dysplasia, Technical University of Applied Sciences Wildau, Esophagus, Google Images, Medical image computing, ESGE, OTH, Gastrointestinal disease, Research, John Radcliffe Hospital, Health, Medical device, Medical imaging

VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ -- Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusive global license from the University of Augsburg and the OTH Regensburg, Technical University of Applied Sciences, in Germany. Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable. Barrett's is a gastrointestinal condition affecting around 150 million people globally. Terms of the transaction were not disclosed.

Key Points: 
  • Satisfai will further develop AI software that will transform the management of Barrett's Esophagus, critically the detection of early esophageal cancer when curable.
  • Satisfai Health's licensing of AI-enhanced software will provide clinicians with faster, more effective diagnostics during endoscopic procedures.
  • Diagnosis entails imaging and biopsies of the esophagus to check for precancerous cells (dysplasia) which can be treated to prevent esophageal cancer.
  • Satisfai Health is a leading medical solutions provider specializing in AI applications for gastroenterology.